

# DNA methylation markers for early detection of colorectal cancer

## Citation for published version (APA):

Lentjes - Beer, M. (2016). *DNA methylation markers for early detection of colorectal cancer: clinical applicability and biological function*. [Doctoral Thesis, Maastricht University]. Uitgeverij BOXPress. <https://doi.org/10.26481/dis.20161202ml>

## Document status and date:

Published: 01/01/2016

## DOI:

[10.26481/dis.20161202ml](https://doi.org/10.26481/dis.20161202ml)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

## Summary



Colorectal cancer (CRC) is one of the most preventable cancers in the world, with over 1,2 million newly diagnosed patients annually. Secondary prevention of CRC, by screening for early disease and precursor lesions, reduces incidence, mortality, morbidity and treatment costs. Over the past two decades, many countries have implemented screening for CRC. Imaging techniques such as flexible sigmoidoscopy, colonoscopy, and CT-colonography and non-invasive stool tests such as guaiac fecal occult blood test (gFOBT) and fecal immunochemical test (FIT) are being used as screening modalities for CRC. Although the sensitivity and specificity of imaging techniques is high, drawbacks are the high costs, complication risks, patient discomfort and requirement of experienced endoscopists. While gFOBT/FIT tests are noninvasive, cheap and easy to use, sensitivity rates for detecting CRCs and advanced lesions are inferior compared to colonoscopy. Additionally, these tests have been shown to obtain high false positive rates, together underscoring the need of sensitive and specific molecular marker tests for early detection of CRC as described in **chapter 1**.

The **aim** of this thesis was to evaluate novel, sensitive and specific promoter methylation markers for noninvasive early detection of CRC and explore the biological function of the identified biomarkers in CRC carcinogenesis.

In **chapter 2**, we analyzed 102 CRCs and 230 noncancerous controls for *GATA4* and *GATA5* promoter methylation which was detected in 70% and 79% of the CRC tissues, respectively. The frequency of *GATA4* and *GATA5* methylation in normal colon mucosa tissue was 6 and 13% respectively. Adenoma tissues collected from CRC patients and noncancerous individuals exhibited methylation frequencies of 33-50% and 41-62%, for *GATA4* and *GATA5* respectively, suggesting that *GATA4/5* methylation is an early event in CRC carcinogenesis. To explore the biomarker potential of the most specific GATA marker, *GATA4* was further analyzed in two series of stool samples collected from two independent series of CRC patients (n=28 and n=47) and colonoscopy negative controls (n=28 and n=30). Using quantitative MSP, a sensitivity of 51-71% and specificity of 84-93% for CRC detection was obtained. In addition, we demonstrated that *GATA4* and *GATA5* proteins exhibit tumor suppressor characteristics. Transfection of *GATA4* and *GATA5* in CRC cell lines significantly suppressed proliferation, migration, invasion, and anchorage-independent growth of CRC cells. A large amount of literature describing the role of GATA transcription factors is available. In **chapter 3**, these studies are summarized in a comprehensive review discussing the function of GATA transcription factors in development and disease.

Another candidate gene which we identified using epigenome-wide screening approaches was the *N-myc downstream regulated gene 4 (NDRG4)*. We examined promoter methylation of *NDRG4* in CRC and adenoma tissues, as described in **chapter 4**. Promoter methylation was detected in two independent series of CRC tissue

with a sensitivity of 86% (n=83) and 70% (n=184) and a specificity of 96%. As described for *GATA4* and *GATA5* methylation, *NDRG4* methylation was also detected in 55% of adenomas from 62 CRC patients and 66% of adenomas from 22 noncancerous controls. Quantitative MSP was used to study promoter methylation of *NDRG4* in stool DNA of CRC patients and healthy, colonoscopy negative controls of 50 years or older in two independent series. The first series (CRCs: n=28, controls: n=45) showed a sensitivity of 71% and specificity of 84% for CRC detection and validation to confirm the test performance in a second series (CRCs: n=47, controls: n=30) yielded a sensitivity of 51% and specificity of 93%. Overexpression of *NDRG4* in human CRC cell lines revealed several tumor suppressive features compared to control transfectants, i.e. reduced colony formation, proliferation and invasion.

Since data about expression and function of *NDRG4* is limited, we explored the expression profile in human and mice by immunohistochemistry, *in situ* mRNA hybridization and Western blotting in **chapter 5**. The *NDRG4* gene is a member of the N-myc downregulated gene family and expression was reported in the central nervous system and heart, which was confirmed in this study. However, in the heart, *NDRG4* expression was not observed in the cardiomyocytes, but was restricted to specialized subendocardial Purkinje fibers. Furthermore, *NDRG4* protein expression was shown in the peripheral nervous system throughout the murine body. Surprisingly in the gastrointestinal tract, no *NDRG4* expression was shown in the epithelial cells, but *NDRG4* expression was confined to the enteric nervous system (ENS), including the submucosal (Meissner's) plexus and myenteric (Auerbach's) plexus. *In situ* hybridization confirmed *NDRG4* expression in the ENS and immunofluorescence assays showed restriction of *NDRG4* to neurons, as *NDRG4* co-localized with the pan-neuronal marker HuC/D but never co-localized with the glia marker GFAP.

To explore the performance of candidate methylation markers in blood, *NDRG4*, *GATA5*, *SYNE1* and *FOXE1* methylation was analyzed in plasma of 154 CRC patients and 444 endoscopy negative controls in **chapter 6**. *GATA5* and *NDRG4* methylation was detected in 18% and 27% of CRC patients, respectively. *SYNE1* and *FOXE1* methylation frequencies of 47% and 46% were observed with specificities of 96% and 93%, respectively. When *SYNE1* and *FOXE1* are combined, the sensitivity increased to 58% with a specificity of 91%. Analysis of *SYNE1* and *FOXE1* in a panel showed a clear stage dependency with sensitivities ranging from 37% in stage I to 100% in stage IV CRC. Functional assays have been performed in order to investigate the biological function of *SYNE1* and *FOXE1* proteins using transfected CRC cell lines. No significant effect on migration or invasion was observed upon *SYNE1* transfection in CRC cell lines. Surprisingly, *SYNE1* transfectants showed an increased proliferation compared to control transfectants. Potential suppressive features of *FOXE1* were shown, as upregulation in CRC cell lines inhibits colony formation.

Finally, in **chapter 7**, the significance of the results obtained in this thesis is discussed. Our findings, as well as the available literature, suggest a better performance of stool-based DNA tests compared to blood-based tests. Partly, this can be explained by the dependency of blood-borne spread of tumor cells predominantly occurring in a late CRC stage in which patients already have a worse prognosis. The data in this thesis also indicate that *NDRG4* performs best of the analyzed stool-based epigenetic markers in CRC detection, which is confirmed by others. Finally, further developments to improve the clinical and analytical sensitivity, such as the identification of novel and/or complementary markers and implementation of cutting-edge techniques in order to increase the sensitivity for CRC detection, are discussed.